Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8564540 | 0.78 | HPGD (0.35) | HPGDSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL8564438 | 0.78 | L3MBTL1 (0.32) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL1526240 | 0.78 | — | — | |
| SCHEMBL8565230 | 0.73 | ALOX5AP (0.31) | — | |
| SCHEMBL13363832 | 0.68 | CYP17A1 (0.39) | HPGDSMN1; SMN2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL14329387 | 0.67 | SLC13A5 (0.40) | HPGDSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL27036925 | 0.67 | MEN1 (0.44) | HPGDSMN1; SMN2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL1586738 | 0.66 | — | — | |
| SCHEMBL663821 | 0.66 | — | — | |
| SCHEMBL27648149 | 0.65 | SYK (0.38) | HPGDSMN1; SMN2KDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321756-B2 | Azole compounds as PIM inhibitors | AMGEN INC. (US) | 2016-04-26 | — | — | US | claimed |
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | AMGEM INC. (US) | 2014-07-03 | — | — | US | claimed |
| EP-2688886-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2014-01-29 | — | — | EP | claimed |
| WO-2012129338-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-09-27 | — | — | WO | claimed |
| EP-1928875-B1 | 2-amino-7,8-dihydro-6H-pyrido(4,3-d)pyrimidin-5-ones, process for their preparation and pharmaceutical compositions containing the same | NOVARTIS AG (CH) | 2011-06-29 | — | — | EP | claimed |
| EP-2252595-A1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | claimed |
| US-7671059-B2 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | NOVARTIS AG (CH) | 2010-03-02 | — | — | US | claimed |
| US-20090305998-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | claimed |
| WO-2009097578-A1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-06 | — | — | WO | claimed |
| EP-1928875-A1 | 2-AMINO-7,8-DIHYDRO-6H-PYRIDOÝ4,3-D¨PYRIMIDIN-5-ONES | Novartis AG (CH) | 2008-06-11 | — | — | EP | claimed |
| US-20070123546-A1 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | CHIRON CORPORATION | 2007-05-31 | — | — | US | claimed |
| WO-2007041362-A1 | 2-AMINO-7,8-DIHYDRO-6H-PYRIDO[4,3-D] PYRIMIDIN-5-ONES | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | claimed |
| EP-0586393-B1 | SUBSTITUTED-2-PHENYL-3-METHOXYPROPENOATES AS FUNGICIDES | ZENECA LTD (GB) | 1998-06-17 | — | — | EP | claimed |
| US-5439910-A | For applying to plants, seeds or soils | ZENECA LIMITED (GB) | 1995-08-08 | — | — | US | claimed |
| US-20170049781-A1 | HSP90 INHIBITOR COMBINATIONS | NOVARTIS AG (CH) | 2017-02-23 | — | — | US | disclosed |
| US-20160346292-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | NOVARTIS AG (CH) | 2016-12-01 | — | — | US | disclosed |
| US-9321756-B2 | Azole compounds as PIM inhibitors | AMGEN INC. (US) | 2016-04-26 | — | — | US | disclosed |
| EP-1928875-A1 | 2-AMINO-7,8-DIHYDRO-6H-PYRIDOÝ4,3-D¨PYRIMIDIN-5-ONES | Novartis AG (CH) | 2008-06-11 | — | — | EP | disclosed |
| US-20070123546-A1 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | CHIRON CORPORATION | 2007-05-31 | — | — | US | disclosed |
| WO-2007041362-A1 | 2-AMINO-7,8-DIHYDRO-6H-PYRIDO[4,3-D] PYRIMIDIN-5-ONES | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346292-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | HSP90B1, HSP90AB1, HSP90AB2P | HPGD 355/4885SMN1; SMN2 4380/4885KDM4E 3885/4885 |
| US-20090305998-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | HPGD 307/4885SMN1; SMN2 4338/4885KDM4E 3050/4885 |
| US-20070123546-A1 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | TYMP, TPMT, TYMS | HPGD 1846/4885SMN1; SMN2 87/4885KDM4E 3174/4885 |
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | PIM1, PIM3, PIM2 | HPGD 2137/4885SMN1; SMN2 4636/4885KDM4E 521/4885 |
| US-20170049781-A1 | HSP90 INHIBITOR COMBINATIONS | HSP90AB1, HSP90B1, HSP90AA1 | HPGD 1539/4885SMN1; SMN2 3559/4885KDM4E 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.